Search results
Results From The WOW.Com Content Network
F. Hoffmann-La Roche AG, commonly known as Roche (/ r ɒ ʃ /), is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland. [4] Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004. [5]
On 2 May 1895, Hoffmann married Adèle La Roche (1876–1938). It was a common practice in Switzerland for married couples to hyphenate the name to incorporate both surnames, so from this point he was often referred to as Fritz Hoffmann-La Roche. They had two sons, Emmanuel (4 May 1896, Basel – 3 October 1932, Basel) and Alfred (25 July 1898 ...
Now that Spark Therapeutics (NASDAQ: ONCE) agreed on a definitive merger with Roche (OTCMKTS:RHHBY) for $114.50 a share, only one question remains for investors. Should investors keep holding ...
Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach ...
Let's put Roche Holding (RHHBY) stock into this equation and find out if it is a good choice for value-oriented investors right now.
In 1990 F. Hoffmann-La Roche AG acquired a majority stake in Genentech. [14] In 2006 Genentech acquired Tanox in its first acquisition deal. Tanox had started developing Xolair and development was completed in collaboration with Novartis and Genentech; the acquisition allowed Genentech to keep more of the revenue. [15]
ZURICH/WASHINGTON (Reuters) - Swiss drugmaker Roche <ROG.S> plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics <ONCE.O> on Tuesday after U.S. and British ...